



## Recent Scientific Advances in Vaccination against Ebola and Marburg Virus Diseases

Guest Editor:

**Dr. Daniela Manno**

London School of Hygiene &  
Tropical Medicine, Keppel Street,  
London WC1E 7HT, UK

Deadline for manuscript  
submissions:

**31 December 2023**

### Message from the Guest Editor

Ebola and Marburg virus diseases are severe haemorrhagic fevers in people and non-human primates (NHP) with a high case-fatality rate.

Both diseases are rare but can cause deadly outbreaks, which in countries with weak health infrastructure or areas of conflict, can remain uncontrolled for months or years, claiming many lives.

Due to climate and environmental change with increasing interactions between humans and wildlife hosts, EVD and MVD outbreaks could become more frequent. It is extremely important to develop and reinforce prevention and control strategies in at-risk countries, to limit the extent of current and future outbreaks.

Vaccines have been an important part of the response to EVD outbreaks due to *Zaire ebolavirus* since the 2014–16 West African outbreak. However, there are no licensed vaccines against Sudan and Marburg virus, although several candidates are under development.

This Special Issue aims to collect recent scientific knowledge and advances in vaccination against Ebola and Marburg virus diseases. We are interested in clinical trials, vaccine roll-out strategies, mathematical modelling, NHP studies and literature reviews.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:**— free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)